Very few things are 100% certain but the odds of a major announcement soon followed by a steady flow of announcements dealing with the pivotal trials of other drugs starting now are very high. I believe AMPE shares will hit new highs instantly when the first announcement comes out and that could be in a few weeks or in a few days.
I believe the investment risk in AMPE is very low and the rewards are unusually high. I am projecting at least $20 by the end of this year and at least $50 by the end of 2014 and continuing.
Their pipeline is quite advanced and is also low risk and they have another 150 drugs to advance as soon as they decide.
I personally believe this is one of the very few to buy and keep buying and hold and do not be tempted to take a profit for at least a couple of years because it will be too easy to miss the huge moves that are coming.
Be patient and average up . . . and average down . .. and hold and hold and watch your money grow!
Be careful for the naysayers and the short interest who don't really see the true picture. They are quick to advise and have not spent the time researching all of the details of this amazing company.
You seem to be well informed on this stock and certainly a fan How do you view their current cash position with clinical trial costs coming up for most of the first half of this year. I have several thousand shares and hope your outlook for this stock are spot on
They have enough cash to last for the next year and to pay for the trials for Optina and Ampion. It is also likely they will raise cash from the spin off of Luoxis Diagnostics with the ORP and also from a licensing deal for Zertane whenever the deal is cleared by the FDa approving the questionnaire for the trial that will be paid for by a major pharma partner.
Cash will not be a problem.
The only problem the company has is that they have never been vetted by Wall Street and therefore very few investors know about them and even fewer will take a position with a major banker endorsing them. Unfortunately, the company does not understand the way the investment markets operate and it is reflected in the price of their stock that is extremely undervalued.
All they need to do is hire somebody to tell their story where everything is cleared by them before it is released but it is told in a way that investors can understand. This lack of understanding will ALWAYS cause the stock to be undervalued until they deal with it like every other successful company in the publicly traded markets.
I think you will do very well to simply hang on and accumulate more whenever you can.
The investors who buy and HOLD will make out great.
Traders have far more fun but make far less money . . . ALWAYS!!!!!
"odds of a major announcement soon followed by a steady flow of announcements dealing with the pivotal trials of other drugs starting now are very high. I believe AMPE shares will hit new highs instantly when the first announcement comes out and that could be in a few weeks or in a few days."
So we should assume a few weeks, rather than "a few days"?
Yes, the FDA will move at its own pace and that time is unknown but expected to be soon because the company was expecting to hear from them on the questionnaire in December. It's difficult displaying patience if you are a trader but patience is the only thing that will pay off in the end.
Volume has dwindled to almost nothing indicating that sellers are exhausted and buyers are just waiting. AMPE shares appear to be positioned for a surprise. Can they drift lower? Yes they can but at some point sellers are finished and buyers step in. It looks like we are at that point now.
The only thing we know for sure is that a surprise announcement is coming and hopefully it is a good one. An announcement that the FDA rejected their questionnaire, could send a short term shockwave but I believe if that happens, it will be short and any selling will be quickly offset by buying from other positive announcements about Optina, Ampion, ORP and NCE001.
I am really surprised that management doesn't take a more aggressive role in supporting shareholder valuations. I don't mean manipulating the stock, I simply mean working hard to get their story out to an investment world that does not even know they exist because they never were vetted through the IPO process like every other company. Management still doesn't understand the importance of this vetting process and doesn't have a clue how to tell their story.
It's really a pity because if they did know how to tell their story and if their company was properly vetted, Ampio would be a $20 stock today and looking to be a $50 stock soon instead of a $3 stock looking to be a $10 stock.